Protein Sciences "avian flu" vaccine enters clinic: 1,000 doses delivered to NIH.

Executive Summary

PROTEIN SCIENCES H5N1 INFLUENZA A VACCINE TO BEGIN CLINICAL TRIALS, the company announced Feb. 3 after delivering over 1,000 doses to the National Institutes of Health. The Hong Kong "avian flu" vaccine trial will enroll healthy adults, laboratory workers and health care personnel who are at risk of exposure to the virus and will have a primary endpoint of safety, National Institute of Allergy and Infectious Diseases Influenza Program Officer Dominick Iacuzio, PhD, told FDA's Vaccines and Related Biologics Advisory Committee Jan. 30.